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Abstract
Background: Bcl-2 is believed to contribute to melanoma chemoresistance. However, expression of Bcl-2 proteins
may be different among melanomas. Thus correlations among expression of Bcl-2-related proteins and in vivo
melanoma progression, and resistance to combination therapies, was investigated.
Methods: Human A375 melanoma was injected s.c. into immunodeficient nude mice. Protein expression was
studied in tumor samples obtained by laser microdisection. Transfection of siRNA or ectopic overexpression were
applied to manipulate proteins which are up- or down-regulated, preferentially, during melanoma progression.
Anti-bcl-2 antisense oligonucleotides and chemoradiotherapy (glutathione-depleting agents, paclitaxel protein-
binding particles, daunorubicin, X rays) were administered in combination.
Results: In vivo A375 cells down-regulated pro-apoptotic bax expression; and up-regulated anti-apoptotic bcl-2,
bcl-xl, and mcl-1, however only Bcl-2 appeared critical for long-term tumor cell survival and progression in vivo.
Reduction of Bcl-2, combined with partial therapies, decreased melanoma growth. But only Bcl-2 targeting plus the
full combination of chemoradiotherapy eradicated A375 melanoma, and led to long-term survival (> 120 days)
without recurrence in 80% of mice. Tumor regression was not due to immune stimulation. Hematology and clinical
chemistry data were within accepted clinical toxicities.
Conclusion: Strategies to target Bcl-2, may increase the effectiveness of antitumor therapies against melanomas
overexpressing Bcl-2 and likely other Bcl-2-related antiapoptotic proteins.
Background
Malignant melanoma is one of the most highly invasive
tumors, and its mortality rates have been rapidly increas-
ing above those of any other cancer in recent years. Sur-
gical resection and systemic chemotherapy are still the
main therapeutic [1]. However systemic chemotherapy
faces two major problems: tumor resistance and toxicity
towards normal tissues [2].
Bcl-2 plays a major role in preventing apoptosis and
has been linked to chemotherapy resistance in melanoma
[3-5]. Bcl-2 also appears able to inhibit e.g. beclin
1-dependent autophagic cell death, which is a nonapop-
totic pathway [6]. However there are striking inconsisten-
cies for the expression of Bcl-2 family proteins with
melanoma progression, particularly for Bcl-2. Roughly
one-third of all available data suggests an increase in
bcl-2 expression with advancing melanoma, while
another third suggests a decrease [7-9]. The general con-
sensus is that pro-apoptotic Bax is decreased with mela-
noma progression while anti-apoptotic Bcl-xl appears to
increase [7]. Despite these controversies it has been
s h o w nt h a tw h e nx e n o g r a f t e di n t os e v e r ec o m b i n e d
immunodeficient mice, 518A2 human melanoma cells
with silenced bcl-2 either failed to grow at all or grew to
tumors of low volume and then completely regressed;
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expanded to be large, necrotic tumors [10]. Besides, we
reported that G3139 (oblimersen sodium, a bcl-2-AS that
selectively targets bcl-2 RNA for degradation and
decreases Bcl-2 protein; Genta Inc.), if combined with a
glutathione (GSH) depleting strategy, facilitates elimina-
tion of murine B16-F10 melanoma liver metastases by
chemoradiotherapy and biotherapy [11]. These facts sug-
gest that Bcl-2 may be an important target. Nevertheless,
whether Bcl-2 is a key target against malignant mela-
noma, as well as the relationship among expression of
Bcl-2-related proteins, in vivo melanoma growth, and
resistance to therapy are still open questions with impor-
tant clinical implications.W eu s e dh u m a nA 3 7 5m e l a -
noma xenografts, widely used as an experimental model
[12], to investigate these questions. Our results show
that, although in vivo growing A375 melanoma cells pre-
ferentially overexpress different Bcl-2-related proteins (as
compared to cultured A375 cells), in vivo targeting of




A375 human melanoma was from the American Type
Culture Collection. A375 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, San Diego,
CA), pH 7.4, supplemented with 10% FCS (Biochrom KG,
Berlin, Germany), 100 units/ml penicillin and 100 μg/ml
streptomycin. Cultures were maintained at 37°C in a
humidified atmosphere with 5% CO2. Cells were harvested
by incubation for 5 min with 0.05% (w/v) trypsin (Sigma,
St. Louis, MO) in PBS (10 mM sodium phosphate, 4 mM
KCl, 137 mM NaCl), pH 7.4, containing 0.3 mM EDTA,
followed by the addition of 10% FCS to inactivate the tryp-
sin. Cell numbers were determined using a Coulter Coun-
ter (Coulter Electronic Inc., Miami, FL). Cellular viability
was assessed as previously reported [11], by measuring try-
pan blue exclusion and leakage of lactate dehydrogenase
activity.
Transfection of red fluorescent protein
The pDsRed-2 vector (Clontech Laboratories Inc., Palo
Alto, CA) was used to engineer A375 clones stably
expressing red fluorescent protein (RFP). This vector
expresses RFP and the neomycin resistance gene on the
same bicistronic message. Cultured A375 cells were
transfected before reaching confluency. Transfection of
the pDsRed-2 vector was carried out using linear 25 kDa
polyethylenimine (PEI) (PolySciences, Inc., Warrington,
PA), as described for adherent cell lines by the manufac-
turer. Cells were incubated for 4 h with the PEI-DNA
complex in 5% of their initial culture medium (DMEM
containing 10% fetal calf serum) volume. After that 4-h
period the culture medium volume was restored to 100%,
and cells were harvested 4 days after transfection. Cells
were then harvested (as above) and subcultured into
selective medium that contained 200 μg/ml of geneticin
(Invitrogen). The level of geneticin was increased to
2,000 μg/ml stepwise. High-Performance Cell Sorting
(DAKO, Copenhagen, Denmark) was used to select
geneticin-resistant A375 clones expressing the RFP
(A375-RFP) and showing high fluorescence emission.
These cells were seeded in 96 wells plates, and their
growth was followed by immune-fluorescence micro-
scopy to select clones showing stable fluorescence
emission.
Animals and diets
Female nu/nu nude mice (6-8 weeks; Charles Rivers
Laboratories, Wilmington, MA) were fed ad libitum on a
standard diet or an equivalent diet but glutamine (Gln)-
enriched diet (GED, 15% of total dietary nitrogen from
Gln; Harlan Teklad Animal Diets & Bedding, Madison,
WI [11]. Both diets were isonitrogenous and isocaloric.
Mice were kept on a 12-h-light/12-h-dark cycle with the
room temperature at 22°C. Procedures involving animals
were in compliance with international laws and policies
(EEC Directive 86/609, OJ L 358. 1, December 12, 1987;
and NIH Guide for the Care and Use of Laboratory Ani-
mals, NIH Publ. No. 85-23, 1985).
Tumor xenografts
For cancer cell xenograft experiments, nu/nu nude mice
were inoculated s.c. (foot-pad) with 10 × 10
6 A375 or
A375-RFP cells per mouse. Tumor volume was calculated
based on two dimensions, measured using calipers, and
was expressed in mm
3 according to V = 0.5a × b
2,w h e r e
a and b are the long and the short diameters of the
tumor, respectively. For histological analysis xenograft
samples were fixed in 4% formaldehyde, paraffin
embedded, and stained with hematoxilin & eosin and
safran. Mice were monitored after inoculation, and
tumor measurements were taken every 2 days.
Isolation and compartmentation of A375-RFP cells
Cell dispersion was carried out in minced tumor tissue as
follows: 1) trypsinization (25 mg of fresh tissue per milli-
liter in Mg
2+ and Ca
2+ free PBS supplemented with 0.2%
trypsin plus 0.5 mM EDTA plus 5 mM glucose, 3 min at
37°C); 2) three washes in PBS; 3) collagenase digestion
(in PBS supplemented with 0.5 mg of collagenase/ml plus
5 mM glucose, 5 min at 37°C) (steps 1 and 3 were per-
formed in Erlenmeyer flasks where the gas atmosphere
was O2/CO2, 19:1). Then cells were washed three times
in PBS and resuspended in 1 ml of ice-cold PBS, filtered
through a 44-μm pore mesh and analyzed using a MoFlo
High-Performance Cell Sorter (DAKO). Fluorescent
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lected into culture chambered slides (Nalge Nunc Inter-
national Corp., Naperville, IL), and harvested and plated
in 25-cm
2 polystyrene flasks (Falcon Labware). Rapid
separation of cytosolic and mitochondrial compartments
was as previously described [13].
Laser microdissection
Excised A375-RFP tumor samples were embedded in
freezing medium OCT (Tissue-Tek, Electron Micro-
scopy Sciences, Hatfield, PA) and flash-frozen using iso-
pentane and following Leica Microsystems’ (Wetzlar,
Germany) instructions to preserve RNA. Five-μm tissue
slices were obtained using a Leica 2800E Frigocut Cryo-
stat Microtome. Tumor cells were separated using a
Leica LMD6000 Laser Microdissection System equipped
with an automated fluorescence module.
RT-PCR and detection of mRNA
Total RNA was isolated using the trizol kit from Invitro-
gen and following manufacturer’s instructions. cDNA was
obtained using a random hexamer primer and a Multi-
Scribe Reverse Transcriptase kit as described by the manu-
facturer (TaqMan RT Reagents, Applied Biosystems,
Foster City, CA). A PCR master mix and AmpliTaq Gold
DNA polymerase (Applied Biosystems) were then added
























Real-time quantitation of the mRNA relative to
GAPDH was performed with a SYBR Green I assay, and
a iCycler detection system (Biorad, Hercules, CA). Target
cDNA was amplified as follows: 10 min at 95°C, then 40
cycles of amplification (denaturation at 95°C for 30 sec
and annealing and extension at 60°C for 1 min per cycle).
The increase in fluorescence was measured in real time
during the extension step. The threshold cycle (CT)w a s
determined, and then the relative gene expression was
expressed as: fold change = 2
-Δ(Δ C
T
) ,w h e r eΔ CT =C T
target - CT GAPDH, and Δ (Δ CT)=Δ CT treated - Δ CT
control [14].
Transfection of small interfering RNA and stable short
hairpin interfering RNA constructs
The PSilencer 3.1-H1 linear vector from Ambion (Austin,
TX) was used to obtain long-term gene silencing. The bcl-
2, bcl-xl, and mcl-1siRNA inserts had sense and antisense
sequences: bcl-xl sense 5’-CAGGGACAGCATATCA-
GAG-3’ and antisense 5’-CTCTGATATGCTGTCCCTG-
3’; bcl-2 sense 5’-AGTACATCCATTATAAGCT-3’ and
antisense 5’-AGCTTATAATGGATGTACT-3’; mcl-1
sense 5’-AAGUAUCACAGACGUUCUCTT-3’ and anti-
sense 5’-GAGAACGUCUGUGAUACUUTT-3’.T h en e g a -
tive control vector, that expresses a hairpin siRNA with
limited homology to any known sequences in human, was
provided by the vector kit (Ambion). Recombinant PSilen-
cer 3.1-H1 vector was transformed into competent E. coli
DH5a (Takara Bio Inc., Shiga, Japan), according to the
supplier protocol, and then bacteria were cultured, har-
vested, centrifuged, and subjected to SDS-alkaline lysis fol-
lowing standard methods (http://www.cshprotocols.org).
Endotoxins were removed from the lysate by simple
extraction-phase separation steps. The plasmid DNA was
further purified by adsorption onto silica using GenElute
Endotoxin-free Plasmid Maxiprep Kit (Sigma). The puri-
fied DNA was diluted to 1 mg/mL and frozen at -20°C.
Transfections with the pSH1-bcl-xl, pSH1-bcl-2, or pSH1-
mcl-1 plasmids were performed using a standard lipofec-
tion method (http://www.cshprotocols.org). Stably trans-
fected clones were selected in medium containing 0.5 mg/
mL geneticin (Invitrogen). Established clones were grown
in medium supplemented with 10% FCS and 0.5 mg/mL
geneticin. Silencing was confirmed by immunoblotting.
The psiRNA-h7SK kit from Invivogen (San Diego, CA),
containing the psiRNA vector expressing shRNA targeting
human bcl-2 gene, was used to generate anti-bcl-2 shRNA
and for cell transfection.
Based on the design principles for shRNA constructs, we
selected RNAi target sites within the open reading frame
of human bcl-xl and mcl-1. The specific base sequences of
the target sites of bcl-xl and mcl-1 were 5’-GGAGAT-
GCAGGTATTGGTGAG-3’ and 5’-ACGCGGUAAUCG-
GACUCA A-3’, respectively. For each target sequences, a
pair of sense and anti-sense strands was designed; their
respective complementary chains were then synthesized
by annealing. The negative control plasmid vector HK
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as a control (it does not target any specific human gene).
Lentiviral infections were done following standard
methodology (Cell Biolabs, San Diego, CA), and the
potency and specificity of each construct were deter-
mined by protein immunoblotting.
bax gene transfer and analysis
The Tet-off gene expression system (Clontech, Palo Alto,
CA) was used to insert the human bax gene and for trans-
fection into A375 cells following manufacturer’s instruc-
tions. Bax protein was detected by western blot (see
above) using monoclonal antibodies anti-human Bax
(Santa Cruz Biotechnology).
Western blot analysis
Cultured cells, harvested as indicated above, or finely
minced tissues were washed twice in ice-cold Krebs-Hen-
seleit bicarbonate medium (pH 7.4). Cell or tissue extracts
were made by freeze-thaw cycles (cells) or homogenization
(tissues) in a buffer containing 150 mM NaCl, 1 mM
EDTA, 10 mM Tris-HCl, 1 mM phenylmethylsulfonyl
fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin, and 1 μg/
ml pepstatin, pH 7.4. The extracts were centrifuged at
10,000 × g for 30 min. Cell/tissue lysate supernatants were
separated for protein determination. All steps were per-
formed at 4°C. Fifty μg of protein (as determined by the
Bradford assay [15]) were boiled in Laemmli buffer and
resolved by 12.0% SDS-PAGE. Proteins were transferred
to a nitrocellulose membrane and subjected to western
blotting using mouse IgG1 monoclonal antibodies raised
against human Bcl-2 or Bcl-xl (Cell Signaling Technology,
Danvers, MA). Blots were developed using horseradish
peroxidase-conjugated secondary antibody and enhanced
chemiluminescence (ECL system, GE Healthcare, Piscat-
away, NJ).
Antisense oligonucleotides
Fully phosphorothioate 18-mer bcl-2-AS were from
Genta Incorporated (Berkeley Heights, NJ). G3139
(human; sequence: 5’-TCTCCCAGCGTGCGCCAT-3’),
G3622 (reversed G3139 sequence control: 5’-
TACCGCGTGCGACCCTCT-3’), and G4243 (G3139
labeled by incorporation of a5 - c a r b o x y f l u o r e s c e i n
nucleotide at the 5’ end).
Analysis of Bcl-2 levels
Bcl-2 protein was analysed by western blotting, and
quantitated in the soluble cell/tissue fraction by enzyme
immunoassay [14] using a monoclonal antibody-based
assay from Sigma (St. Louis, MO) (one unit of Bcl-2
represents the amount of Bcl-2 protein in 1000 non-
transfected A375 cells).
GSH measurement
GSH in tumor and non-tumor tissues was determined,
following procedures previously described [16], by liquid
chromatography-mass spectrometry using a Quattro
micro triple-quadrupole mass spectrometer (Micromass,
Manchester, UK) equipped with a Shimadzu LC-
10ADVP pump and SCL-10AVP controller system with
an SIL-10ADVP autoinjector (Shimadzu Corporation,
Kyoto, Japan). Tissue/blood sample collection and pro-
cessing were performed according to published metho-
dology, where rapid N-ethylmaleimide derivatization is
used to prevent GSH auto-oxidation [17].
Irradiation procedure
X rays were administered using a 6 KeV SL75 linear
accelerator from Philips. Each mouse was anesthetized
with nembutal (50 mg/kg i.p.), and fixed on a Perspex
platform. Radiotherapy was administered at a rate of 2.0
Gy/min. The radiation beam was focused only on the
tumor. The irradiated area was fixed to a maximum of
1.5 cm
2, and the rest of the mouse had lead protection.
Evaluation of therapy-induced in vivo toxicity
This included the following parameters: animal weight,
complete blood cell count, and standard blood chemistry.
Serum cytokines
Blood samples were centrifuged at 14,000 rpm for 10 min
at 4°C to separate the serum. Concentrations of IL-1a,I L -
1b,I L - 2 ,I L - 6 ,I L - 1 0 ,I L - 1 2 ,T N F - a,a n dI F N - g in the
serum was determined using mouse cytokine ELISA kits
from Innovative Research (Novi, MI); whereas IFN-a was
measured using a kit from Antigenix Station (New York,
NY). Manufacturer’s protocol was followed in all cases.
Results were read with a Dynex MRXII ELISA reader
(ThermoLabsystems, Chantilly, VA). Quantification of
secreted cytokines was accomplished by normalization of
the ELISA data with a standard cytokine dose curve.
Statistical significance
Data were analyzed by Student’s t test.
Results
Expression of Bcl-2 family proteins in A375 melanoma
in vivo
Our first task was to investigate if the expression of Bcl-2
and related proteins affecting apoptosis changes during
melanoma growth in vivo relative to growth in vitro.A s
compared to cultured in vitro controls, A375 cells grow-
ing in vivo significantly down-regulate expression of pro-
apoptotic bax; and up-regulate anti-apoptotic bcl-2, bcl-xl
and mcl-1 (Figure 1). Thus suggesting that A375 growth
in vivo is associated with activation of pro-survival
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t h ei n c r e a s ei nbcl-xl expression were in agreement with
previous results where these changes were initially asso-
ciated with clinical progression of melanoma [7]. However,
it was still unclear whether the decrease in the pro-death
Bax and/or the increase in the anti-death Bcl-2, Bcl-xl, and
Mcl-1 proteins are merely a defence response against
immune and microenvironment challenges, or were neces-
sary for in vivo melanoma progression. In order to answer
this question, mice were inoculated with A375 cells trans-
fected with the Bax gen (A375/Tet-bax), or with siRNA
specific for Bcl-2 (A375/bcl-2-siRNA), Bcl-xl (A375/bcl-xl-
siRNA), or Mcl-1 (A375/mcl-1-siRNA).
Specific bcl-xl or bcl-2 silencing inhibits in vivo A375
melanoma growth
After inoculation, control A375 xenografts grow exponen-
tially. Ectopic bax overexpression (Figure 2A) did not
affect A375 growth as compared to controls (Figure 2E).
Specific siRNA-induced silencing of mcl-1 (Figure 2D) did
not affect significantly melanoma growth (Figure 2E). Spe-
cific siRNA-induced silencing of either bcl-xl (Figure 2B)
or bcl-2 (Figure 2C) sharply decreased melanoma growth
(Figure 2E), but the involvement of these two anti-
apoptotic gene family members was not equivalent. While
A375/bcl-xl-siRNA tumors tended to progress slowly (167
±38 mm
3, approximately 13.8% of the tumor volume cal-
culated for control A375 tumors 3 weeks after inocula-
tion), A375/bcl-2-siRNA tumors tended to regress (86 ±
25 mm
3 1 week after inoculation, and < 20 mm
3 3w e e k s
after inoculation) (Figure 2E) (expression levels of the rele-
vant apoptosis-related proteins in the tumors assessed in
Figure 2E are presented in Additional file 1 Table S1).
Therefore, despite the changes in gene expression dis-
played in Figure 1, in vivo A375 melanoma growth appears
highly dependent on Bcl-2, whereas Bcl-xl and Mcl-1
expression did not substitute for Bcl-2. Our next task was
to test if Bcl-2 represents a key therapeutic target to
reduce melanoma cell survival in vivo.
Tumor Bcl-2 depletion in vivo
In a previous report the bcl-2-AS G3139 was found effec-
tive in depleting selectively Bcl-2 in metastatic B16- F10
melanoma cells [11]. Recently, periodic G3139 mono-
therapy (high dose, i.v., Q2-3 days) yielded superior anti-
tumor efficacy (including different experimental models)
when compared with low-dose daily i.v. injections [18].
Consequently, brief high-dose i.v. infusions are being
Figure 1 Expression of pro-death and anti-death Bcl-2 genes in A375 melanoma xenografts. A375-RFP cells were isolated by laser
microdissection (as indicated under Methods) 7, 14, and 21 days after tumor inoculation. The data, expressing fold change (quantitative RT-PCR,
see under Methods for calculations), show mean values ± S.D. for 5-6 different experiments (*p < 0.05 for all genes displayed comparing A375-
RFP cells isolated from in vivo growing tumors versus 24 h-cultured A375-RFP cells). No significant differences in expression of Bcl-2-related
genes when control A375 and A375-RFP cells were compared in vitro (not shown).
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Page 5 of 13Figure 2 Effect of shRNA-induced bcl-xl, bcl-2, or mcl-1 silencing and of ectopic bax overexpression on A375 xenograft growth.s i R N A -
induced bcl-xl, bcl-2, or mcl-1 silencing was used for preliminary in vitro experiments, whereas cells stably expressing shRNAs were used for in vivo
experiments (see under Methods). (A) western blots of Bax in A375 and A375/Tet-bax cells. (B, C, D) western blots of Bcl-xl, Bcl-2, and Mcl-1,
respectively, in A375 cells transfected with bcl-xl siRNA, bcl-2 siRNA, mcl-1 siRNA, or non-specific (NS) siRNA. (E) in vivo growth of A375 (●), A375/bcl-
xl-shRNA (■), A375/bcl-2-shRNA (○), and A375/Tet-bax cells (□). Western blots correspond to cultured transfected cells, and are similar to those
obtained in extracts of xenografts (see Methods) 1 or 2 weeks after tumor inoculation (not shown), thus indicating stability of each plasmid expression.
Tumor growth (E) was measured during a 3-week period. Data are means ± S.D. of 9-10 mice per group. The significant test refers, for all groups (E), to
the comparison between A375/bcl-xl-shRNA, A375/bcl-2-shRNA, or A375/Tet-bax cells and A375 controls (*p < 0.01). A375/bcl-2-shRNA was also
compared versus the A375/bcl-xl-shRNA group (
+p < 0.01) (E). Rates of tumor growth obtained with A375/mcl-1-shRNA cells were not significantly
different from those displayed for A375/Tet-bax cells (□) (E) (not shown). Rates of tumor growth obtained with A375 cells transfected with empty Tet-
off vector or with NS shRNA were not significantly different from those displayed for untransfected A375 controls (●) (E) (not shown).
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safety and efficacy of G3139 in combination with other
agents (http://www.genta.com). We observed A375-RFP
tumor staining after in vivo administration of 20 mg
G4243 [carboxyfluorescein (green fluorescence)-labeled
G3139]/kg (i.v.). Green fluorescence accumulated within
the tumor cells thus showing that in vivo administered
bcl-2-AS oligonucleotides crossed the tumor cell plasma
membrane (see Additional file 1 Figure S1A).
We found that: a) G3139 reduced Bcl-2 expression in
A375 tumors but had no significant effect in different
non-tumor tissues (including liver, brain, lung, heart, kid-
ney, or skeletal muscle; although, as an example, only
data for the liver are shown); b) G3622 (reversed
sequence), as compared to physiological saline-treated
controls, does not deplete significantly Bcl-2 neither in
the tumor nor in non-tumor tissues (see Additional file 1
Figure S1B). The lack of significant reduction of murine
Bcl-2 expression in non-tumor tissues could be consis-
tent with the presence of two mismatches between the
human bcl-2 sequence targeted by G3139 and the murine
bcl-2 sequence. Nevertheless, G4244 (the murine bcl-2-
AS from Genta Inc.) was found to deplete Bcl-2 in tumor
but not in non-tumor tissues in the murine B16-F10 mel-
anoma model [11].
Tumor GSH depletion in vivo
Resistance to chemo- and radiotherapy frequently associ-
ates with high GSH content, and GSH depletion can
restore sensitivity to radiotherapy [19-21]. Depletion of
Bcl-2 has been confirmed to decrease intracellular GSH
[22]. As shown in the B16 melanoma model, selective
GSH depletion in tumor cells can be achieved by com-
bining in vivo administration of G3139 [increases GSH
efflux through cystic fibrosis transmembrane conduc-
tance regulator (CFTR); a multidrug resistance protein 1
(MRP1)-like member of the ABC family of transport pro-
teins], verapamil (VRP, accelerates the loss of GSH by
activation of MRP1), and acivicin [ACV, blocks g-gluta-
myl transpeptidase (g-GT) and prevents recycling of L-
cysteine from the extracellular pool of GSH] [11]. Thus,
as part of a general chemotherapy approach, we assayed
this strategy in xenografted A375 human cells.
GSH efflux in control 48-h cultured A375 cells was
1.5 ± 0.3 nmol/10
6 cells × h (n = 5), whereas GSH efflux
in A375 cells cultured × 48 h in the presence of 2 μM
G3139 and 1 μg cytofectin/ml was 3.5 ± 0.5 nmol/10
6
cells × h (n = 6, P < 0.01) (Bcl-2 levels in control and
G3139-treated cultured cells were 28 ± 3 and 3 ± 1
units/mg protein, respectively). GSH efflux in A375 cells
cultured × 48 h in the presence of 10 μMV R Pw a s2 . 5
± 0.4 nmol/10
6 cells × h (n = 7, P < 0.01). g-GT activity
w a s3 0±5a n d3±1m U / 1 0
6 cells in 48-h cultured
A375 cells incubated, respectively, in the absence or in
t h ep r e s e n c eo f1μM ACV (n = 6, P < 0.01). In vivo
administration of G3139, VRP, and ACV decreased GSH
levels in the A375 tumor, but did not affect significantly
the GSH content of different normal tissues (see Addi-
tional file 1 Table S2).
In vivo administration of G3139 + VRP + ACV
decreased GSH levels in the A375 tumor, but did not
affect significantly the GSH content of different normal
tissues (see Additional file 1 Table S2). Single adminis-
tration of any of these compounds did not decrease
tumor GSH (Table S2). In the cancer cells, likely due to
in vivo adaptation mechanisms, only when increasing
efflux (through two different channels) associates with
synthesis limitation a sharp decrease in intracellular
GSH levels is obtained.
Elimination of A375 melanoma growing in vivo
For conventional chemoradiotherapy paclitaxel protein-
binding particles (PAC.PBP), daunorubicin (DNR), and
X-rays were selected on the basis of previous in vitro
studies, including screening most chemotherapeutic
drugs used against human melanoma cells, also includ-
ing vincristine, vindesine, vinblastine, bleomycin, metho-
trexate, arsenate, cisplatin, carmustine, dacarbazine,
temozolomide, and vemurafenib (not shown). We
designed a protocol based on four basic ideas: a) treat-
ment will begin only when the tumor has reached a
volume that represents a clinically relevant structure; b)
fractionated and early administration of cytotoxic che-
moradiotherapy, associated with Bcl-2 and GSH deple-
tion, should kill heterogeneous melanoma cell subsets
with different resistance phenotypes and may enhance
uptake of G3139 into tumor cells (as it occurs with
ionizing radiations [23]; c) since PAC.PBP + DNR was
the best combination against A375 cells (100% tumor
cell deaths in vitro using human MTDs; data not
shown), DNR should be included at the end to eliminate
possible cancer cell survivors; d) the GED, by decreasing
mitochondrial GSH [24], should facilitate G3139-
induced release of proapoptotic signals [10]. GED-
induced depletion of tumor mitochondrial GSH was
confirmed by comparing A375-RFP cells isolated from
mice fed a standard diet or a GED (mitochondrial GSH
levels were 8.5 ± 2.7 or 4.2 ± 1.5 nmol/10
6 cells, respec-
tively, n = 5 in both cases, P < 0.05).
Drug doses and administration sequences (see the
caption in Table 1) were evaluated in preliminary stu-
dies to optimize each element in combination-treatment
protocols. One day after finishing the treatment regi-
men, combination of X rays + PAC.PBP + DNR had
decreased tumor volume to approx. 22% of control
values (treated with physiological saline) (Table 1).
Addition of G3139 or G3139 + VRP + ACV further
decreased tumor volume to less than 10% of controls
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days after the treatment, only the full combination (X
r a y s+P A C . P B P+D N R+G 3 1 3 9+V R P+A C V )
induced a complete tumor regression (Table 1). Most
mice (80%, Figure 3) treated with the full combination
were completely cleared of tumor cells, as shown by sur-
vival beyond 120 days with no detectable tumor recur-
rence. The timing and order of treatment (Table 1) had
significant impact on the efficacy of the regimen. If X
rays were administered later (e.g. on days 11 and 12 or
on days 14 and 15), or if PAC.PBP is administered later
(on days 13 and 16) and DNR earlier (on days 7 and
10), the tumor volume was never below of 50 mm
3 in
mice 1 day after receiving the full treatment (data not
shown). Moreover, in mice fed a standard diet, the full
treatment was unable to induce a complete tumor
regression (55 ± 17 mm
3, n = 12, 15 days after the
treatment).
Complete blood cell count and standard blood chemis-
try were measured to evaluate the side effects of the treat-
ment that eliminated A375 xenografts. Side effects
included e.g. anemia, severe lymphopenia and neutropenia,
and an increase of several tissue-damage-related enzyme
activities in plasma, including aspartate aminotransferase,
alanine aminotransferase, g-glutamyl transpeptidase, alka-
line phosphatase, and lactate dehydrogenase (see Addi-
tional file 1 Table S3). However, in the mice cleared of
tumor (80%, > 120-day survival; Figure 3), most hematolo-
gic and clinical chemistry measures returned to normal
values (untreated, non-tumor-bearing mice) 30 days after
treatment (see Additional file 1 Table S3). Although the
side effects measured in the treated mice are significant,
such complications are commonly observed and managed
in melanoma patients receiving current clinical therapies.
Bcl-2 targeting- and chemoradiotherapy-induced
elimination of A375 melanoma is not due to immune
stimulation
Immune stimulation has been observed with CpG-con-
taining antisense oligonucleotides [25]. Previous studies
have shown nonantisense effects, such as production of
reactive oxygen species and immunostimulatory action,
elicited by bcl-2 antisense oligodeoxynucleotides (bcl-2-
AS) through cytosine-phosphate-guanosine (CpG)-motifs
[26]. For instance, CpG oligonucleotides may enhance
the tumor response to radiotherapy [27]. Theoretically all
phosphorothioate oligos, even those that do not contain
CpG motifs (and G1339 has two them), will bind to
TLR-9, are hence immunostimulatory to some extent,
and should increase levels of circulating cytokines (some
of them potentially tumoricidal) [28]. In particular, CpG
oligonucleotides administered in single peritumoral sub-
cutaneous injections three times per week resulted in ele-
vated plasma levels of IL-12 and significant inhibition of
the growth of melanoma xenografts by approx. 60% com-
pared to the saline control [29]. Therefore it is a matter
of discussion which property is the main responsible of
the antitumor effects. Is the melanoma shrinkage due to
the down regulation of Bcl-2 and resulting chemosensiti-
zation? Or is it due predominately to increased cytokine
activity with Bcl-2 playing a lesser role in vivo? To answer
this important question we measured leukocyte and
Table 1 Effect of Bcl-2 and GSH depletion on the in vivo response of A375 melanoma to chemoradiotherapy.
Tumor volume measurement (mm
3)
Days after treatment 1 15
Treatment PS G3139 G3139+ACV+VRP PS G3139 G3139+ACV+VRP
None 192 ± 59 138 ± 28 175 ± 61 807 ± 240 953 ± 330 618 ± 265
PAC.PBP 153 ± 61 97 ± 31 74 ± 30*
+ > 1000 731 ± 148 547 ± 138
DNR 220 ± 70 156 ± 49 117 ± 44* > 1000 > 1000 > 1000
PAC.PBP + DNR 83 ± 26
++ 66 ± 18
++ 45 ± 12**
++ > 1000 488 ± 177 352 ± 95
X rays 263 ± 88 84 ± 26**
+ 71 ± 25**
++ > 1000 769 ± 260 641 ± 189
X rays + PAC.PBP 150 ± 44 93 ± 15*
+ 105 ± 38 643 ± 167 161 ± 75**
++ 96 ± 36**
++
X rays + DNR 246 ± 71 96 ± 36** 53 ± 9**
++ 926 ± 225 694 ± 166 502 ± 190**
X rays + PAC.PBP + DNR 42 ± 14
++ < 20 < 20 514 ± 116
+ 43 ± 12**
++ N.D.
The treatment regimen is indicated in the scheme placed above the table. Mice were fed ad libitum on a GED (see Methods) starting 1 week before tumor
inoculation. Verapamil (VRP, 1 mg/kg) and acivicin (ACV, 2 mg/kg) were given i.p. daily (1 dose × day) starting 7 days after tumor cell inoculation (days 7 to 16).
G3139 (20 mg/kg) was given i.v. on days 7, 10, 13, and 16. Paclitaxel protein-binding particles [PAC.PBP, 32.5 mg/kg (human MTD × 5)] was given i.v. on days 7
and 10. Daunorubicin [DNR, 3.125 mg/kg (human MTD × 2.5)] was given i.v. on days 13 and 16. Animal doses of chemotherapy were calculated using NCI
guidelines (www.cancer.gov) and the conversion factor for mice published by the FDA (www.fda.gov). Mice received fractionated X-ray therapy (15 Gy/day
focused on the tumor) on days 8 and 9. Total X-ray dose was selected, as effective and safe, after testing a range of 5 to 40 Gy in the absence or in the presence
of the full combined therapy (not shown). Mice were sacrificed when tumor volume was > 1000 mm
3. Tumor size on day 7 after inoculation was, in all cases, of
50-75 mm
3. Body weight of mice treated with the full combination was approximately 75% and 83% of controls (treated with physiological saline) 1 or 15 days,
respectively, after the treatment. Data are means ± S.D. for 18 to 20 different mice. N.D., nondetectable. Histologic examination (see Methods) confirmed that, in
16 of 20 (80%) mice, the full treatment achieved a complete tumor regression. *P < 0.05, **P < 0.01 comparing for each condition G3139- or G3139 + VRP +
ACV-treated tumor-bearing mice versus treatment with physiologic saline.
+P < 0.05,
++P < 0.01 comparing, in mice treated with physiologic saline, G3139, or
G3139 + VRP + ACV, all experimental conditions versus none under treatment.
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Page 8 of 13Figure 3 Effect of treatment-induced regression of A375 melanoma xenografts on host survival.A 3 7 5m e l a n o m a - b e a r i n gm i c ew e r e
treated as in Table 1. Host survival was studied in the following treatment conditions: (○) physiologic saline; (●) G3139 + VRP + ACV; (□) G3139
+ VRP + ACV + PAC.PBP + DNR; (■) G3139 + VRP + ACV + X-rays; (Δ) G3139 + VRP + ACV + PAC.PBP + DNR + X rays. Representative photos
here below correspond to two control mice treated with physiological saline and two mice treated with the full combination therapy that had
> 120-day survival. Data are means + S.D. for 20 different mice in each experimental condition.
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Page 9 of 13cytokine levels in circulating blood and serum, respec-
tively. We focused on the treatment conditions that led
to complete melanoma regression in vivo.A ss h o w ni n
Table 2 the combination of G3139 + VRP + ACV + PAC.
PBP + DNR + X rays (see Table 1) causes a profound leu-
copenia with lower levels of all white cell subtypes as
compared to controls. Serum cytokine levels (including
IL-1a,I L - 1 b, IL-2, IL-6, IL-10, IL-12, TNF-a,I F N - g and
IFN-a) were lower in A375 melanoma bearing mice trea-
ted with G3139 + VRP + ACV + PAC.PBP + DNR + X
rays than in controls treated with physiological saline
(Table 2). Thus it appears obvious that, in our therapeu-
tic strategy, melanoma regression is not due to immune
stimulation. In fact, immune stimulation by CpG motifs
and antitumor effects in SCID mice could be indepen-
dent effects [30]. As shown in Table 1 it should be noted
that G3139 administration does not affect melanoma
growth; and that G3139 + chemotherapy PAC.PBP +
DNR only decreases melanoma growth by approx. 50% (a
partial inhibition followed later by an accelerated tumor
growth, not shown). Therefore, as suggested by the data
in Table 1 the use of G3139, as a single agent or com-
bined with chemotherapy, may render only limited effects
against advanced melanoma.
Discussion
The inability of undergo apoptosis in response to che-
motherapy and other external stimuli poses a selective
advantage for tumor progression, metastasis formation as
well as resistance to therapy in melanoma [31]. Recently
numerous cellular pathways important to melanoma cell
proliferation, apoptosis, or metastases have been shown to
be activated. Activation occurs through specific mutations
(e.g. B-Raf, N-Ras,a n dPTEN) or changes in proteins
expression (e.g. PTEN, Bcl-2, NF-B, CDK2, and cyclin
D1) [32]. Thus, it is generally assumed that multi-target-
directed therapies will be needed to produce significant
clinical benefits in patients [32].
In particular, bcl-2 overexpression in different human
melanoma cells appears to favour tumor progression-
associated properties and in vivo growth [33], thus mak-
ing Bcl-2 a rational target for anticancer therapy [34].
Nevertheless, as stated in the Background section, analy-
sis of clinical melanomas suggests large variations in
expression of Bcl-2 and related proteins, which possibly
depend on the growth rate, the TNM staging, and/or the
type of therapies applied before clinical samples were
obtained. Obviously, potential adaptive changes of pro-
tein expression, under in vivo conditions, could be
reflected by changes in the anti-death resistance potential
of melanoma cells.
Studies by Stein and coworkers showed that the Bcl-2
protein profoundly affects the ability of human 518A2
melanoma cells to grow as human tumor xenografts [10].
However, in vivo expression or silencing of other death-
related proteins was not evaluated in these studies. In
fact it appears reasonable to expect that, in addition to
Bcl-2, other Bcl-2-related proteins may also play growth-
regulating effects in human melanoma.
We have addressed these questions in the A375 mela-
noma model showing that A375 cells, in vivo,d o w n - r e g -
ulate pro-death bax expression, and up-regulate anti-
death bcl-2, bcl-xl,a n dmcl-1 relative to cells cultured in
vitro (Figure 1). The impact of these changes were inves-
tigated by reversing them in vivo using modified A375
cells grown as xenografts (Figure 2). Forced bax overex-
pression or mcl-1 silencing did not affect A375 growth as
compared to controls (Figure 2E). A375 melanoma cells
Table 2 Cytokine levels in serum of A375 melanoma-bearing mice
Cytokines Non-Tumor bearing mice Tumor-bearing mice
Days after tumor inoculation
71 1 1 7
Full treatment...- - + -+
TNFa 9 ± 3 37 ± 12** 156 ± 29** 85 ± 15**
++ 215 ± 61** 25 ± 7**
++
IFNa 7 ± 2 12 ± 6 15 ± 7* 10 ± 3 17 ± 8* 6 ± 3
+
IFNg 12 ± 3 16 ± 3 17 ± 2* 13 ± 4 25 ± 7** 8 ± 4
++
IL-1a 4 ± 1 15 ± 4** 20 ± 6** 12 ± 1**
+ 18 ± 4** 5 ± 1
++
IL-1b 3 ± 1 8 ± 2** 7 ± 2* 5 ± 0.5* 10 ± 2** 7 ± 1**
IL-2 78 ± 15 116 ± 32* 200 ± 43** 84 ± 12
++ 177 ± 36** 94 ± 14
+
IL-6 39 ± 14 397 ± 147** 1244 ± 296** 795 ± 206**
+ 1063 ± 253** 52 ± 15
++
IL-10 86 ± 22 111 ± 39 61 ± 13 77 ± 13 93 ± 27 72 ± 18
IL-12 3 ± 0.5 92 ± 27** 318 ± 76** 12 ± 4**
++ 244 ± 67** 14 ± 3**
++
Blood was collected from the tail vein every 6 h during the 24-h period of each indicated day. The days after tumor inoculation refer to those indicated in the
scheme placed above the table 2. Full treatment refers to the combination of G3139 + VRP + ACV + PAC.PBP + DNR + X rays (as in table 2) that achieves a
complete A375 melanoma regression. Data are mean values of the peak serum cytokine concentrations ± S.D (pg/ml) measured in 7-8 different animals. *P <
0.05, **P < 0.01 comparing for each condition versus non-tumor-bearing mice.
+P < 0.05,
++P < 0.01 comparing tumor-bearing mice receiving the full treatment
(+) versus tumor-bearing mice treated with physiologic saline (-).
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A375 controls (Figure 2E). In parallel, we found that
A375 with reduced bcl-2 expression failed to grow after
implantation and tended to regress (Figure 2E). Thus
suggesting that Bcl-xl and Bcl-2 are not functionally
interchangeable in vivo, and that Bcl-2 alone (despite
down regulation of bax and up-regulation of bcl-xl)
could be a relevant target in melanoma therapy.
Why would Bcl-2, which is only one of the many regu-
lators of apoptosis, be essential for melanoma progres-
sion in vivo (Figure 2E)? The more aggressive behaviour
of different Bcl-2 overexpressing melanomas was asso-
ciated to an increase in several metalloproteases (e.g.
MMP-2, MMP-7, and MT1-MMP) expression, and to an
elevated microvessel density as compared to parental
cells [33]. In agreement with those findings it was shown,
e.g., that a) Bcl-2 promotes invasion and lung metastasis
of Bcl-2 overexpressing non-small cell lung cancer cells
by inducing matrix metalloproteinase-2 [35]; b) mem-
brane type-1 matrix metalloproteinase promotes human
melanoma invasion and growth [36]; and c) Bcl-2 overex-
pression in human melanoma cells increases angiogenesis
through VEGF mRNA stabilization and HIF-1-mediated
transcriptional activity [37],a n dr e g u l a t e sH I F - 1 a l p h a
protein stabilization in hypoxic melanoma cells via
HSP90 [38]. Nevertheless these possibilities have been
questioned since: a) Bcl-2 down-regulation in 518A2
melanoma cells did not associate with down-regulation
of MMP-2 or MMP-9; and b) also in 518A2 tumor cells,
transfected with the Bcl-2 plasmid and growing as xeno-
grafts, extensive necrosis in the setting of very poor vas-
cularity was observed [10]. Therefore, correlations
between Bcl-2 overexpression and MMPs or angiogenesis
lack experimental evidence. Besides it is known that Bcl-
2 and Bcl-xl are antiproliferative by facilitating arrest at
G0-G1 [38]. The dual functions in apoptosis and cell
cycle are coordinately regulated by the multi-domain Bcl-
2 family members and suggest that survival is maintained
at the expense of proliferation [39].
Anti-bcl-2 antisense therapy decreases Bcl-2 in A375
tumors (Additional file 1 Figure S1B). G3139, if combined
with VRP + ACV, also depletes melanoma GSH (Addi-
tional file 1 Table S2). Bcl-2 down-regulation in melanoma
causes sensitization to chemoradiotherapy (Table 1). How-
ever, only combined depletion of Bcl-2 and GSH leads to a
complete xenografts regression by chemoradiotherapy
(Table 1), and long-term survival of the treated mice (Fig-
ure 3). Blc-2 inhibits GSH efflux and, thus, favours GSH
accumulation within the cancer cell [14]. The use of
G3139 facilitates GSH efflux [22]. However, unless this is
combined with GSH efflux facilitation through MRP1 and
a gamma-glutamyl-transpeptidase inhibitor to prevent de
novo GSH synthesis, the cancer cell responds with a
rebound in GSH synthesis (see e.g. [22]).
G3139 decreases Bcl-2 levels to less than 30% of con-
trol values se the legend to Table 1) but it does not
inhibit tumor growth. Hence, until more effective and
specific anti-Bcl-2 agents/treatments are developed, the
Bcl-2/GSH double targeting in combination with che-
moradiotherapy appears a reasonable, clinically feasible,
and effective approach.
A phase III trial designed to confirm safety and efficacy
results of G3139 combined with dacarbazine in mela-
noma patients (not previously receiving chemotherapy),
indicated that G3139 has an acceptable clinical safety
profile [40], although positive impact on different clinical
end points, including progression-free survival and over-
all survival, has not been obtained (see http://www.genta.
com). Thus indicating that G3139 + dacarbazine is not
the right strategy, as suggested by our data (Table 1).
Nevertheless standard chemoradiotherapy, and additional
drugs (GED, VRP, and ACV), have known clinical appli-
cations and its use in melanoma has been recently dis-
cussed [11].
Optimization of chemoradiotherapy and antisense
therapy targeting bcl-2 (Table 1) simplifies the treatment
that eliminated metastatic B16 melanoma from the
mouse liver, since avoids the need of TNF-a,a n dI F N - g
administration (and their side effects). Thus, our strat-
egy likely appears more patient-friendly and effective
(Figure 3). Moreover, our combination therapy appears
easy to standardized since effective doses in human
melanoma-bearing mice are within clinically acceptable
and tolerated ranges.
Finally it is important to remark that recently devel-
oped target therapies for the treatment of late-stage mel-
anoma were also considered for our combination
strategy. This including vemurafenib (a B-Raf enzyme
inhibitor also known as PLX4032) [41] and ipilimumab
(a fully human antibody that binds to cytotoxic T lym-
phocyte-associated inhibitor, which may in turn augment
T-cell responses to melanoma cells) [42]. B-Raf knock-
down leads to apoptosis in them e l a n o m ac e l ll i n eA 3 7 5
[43], however it did not come up as the best option on
the basis of our preliminary in vitro studies (see under
Results). On the other hand ipilimumab may be very use-
ful if applied after our immunosuppressive combination
therapy, during the recovery phase, were in some cases a
few malignant melanoma cells may have managed to
survive.
Conclusions
Our results suggest that Bcl-2 may be an important target
against melanoma progression and resistance to therapy,
not only for its antiapoptotic role but also for regulating
GSH levels and, likely, for other unrevealed mechanisms.
Bcl-2 appears to play a prevalent role even when other
Bcl-2 family protein are also overexpressed. However
Mena et al. Journal of Translational Medicine 2012, 10:8
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by itself, does not inhibit tumor growth. Even the simul-
taneous depletion of GSH and Bcl-2 is uneffective unless
chemoradiotherapy is also applied. Nevertheless, before
considering practical applications, the importance of Bcl-
2 and the mechanisms involved must be investigated in a
sufficiently large number of human melanomas showing
different rates of expression of Bcl-2 and Bcl-2-related
proteins. If Bcl-2 and/or other(s) related protein(s) is/are
identified as key target(s), our strategy (or variations of it)
may improve the poor prognosis of advance melanoma-
bearing patients.
Additional material
Additional file 1: Figure S1: In vivo G3139 uptake and Bcl-2
depletion in A375 melanoma cells. (A) In vivo distribution of blc-2-AS
in RFP-expressing A375 tumors growing in mice treated with G4243 (20
mg/kg): transmission, red and green fluorescence, and nuclei which were
labeled with Hoescht 33342 (Sigma) [11]. Microscopic examination (A)
was performed 24 h after G4243 administration, whereas Bcl-2 levels (B)
were measured 24, and 48 h after G4243 administration. Human and
murine Bcl-2 were quantified by enzyme immunoassay (see Methods) in
A375 and murine tissue samples, respectively, obtained after treating
xenografted mice (7 days after A375 inoculation) with physiological
saline or 20 mg G3622 or G3139 (bcl-2-AS)/kg. Histological examination
showed that in tumor tissue samples the highest % of tissue mass (>
92% in all cases) corresponds to A375 cells. Bcl-2 levels, measured as
units/mg protein remained < 30% of control values in all mice treated
with G3139 alone or in combination with the other treatments displayed
in Table 1 (data not shown). Bars are means ± S.D. of 4-5 different
experiments, *P < 0.01 (comparing each bcl-2-AS versus controls).
Treatment with G3139 or G3622 did not affect significantly Bcl-2 levels in
brain, lung, heart, kidney, or skeletal muscle relative to untreated controls
(data not shown). Table S1: Expression of bax, bcl-2, bcl-xl, and mcl-
1 in A375 control xenografts or in tumors of mice inoculated with
A375/Tet-bax, A375/bcl-xl-shRNA, A375/bcl-2-shRNA, or A375/mcl-
1-shRNA cells. A375-RFP cells were isolated by laser microdissection (as
indicated under Methods) 14 days after tumor inoculation. The data,
expressing fold change (quantitative RT-PCR, see under Methods for
calculations), show mean values ± S.D. for 4 different experiments (*p <
0.05 for the genes displayed comparing control A375-RFP cells and their
different variants, isolated from in vivo growing tumors, versus 24 h-
cultured A375-RFP cells; +p < 0.05 for all genes displayed comparing
control A375-RFP cells versus their different variants).Values obtained in
A375-RFP cells transfected with the negative control plasmid vector HK
were not significantly different from those obtained in controls (not
shown). Table S2: GSH content in tumor cells and tissues from A375
melanoma xenograft-bearing mice treated with G3139, VRP, and/or
ACV. The 10 days combination therapy schedule is shown. G3139 (20
mg/kg each 72 h, i.v.), VRP (1 mg/kg × day, i.p.), ACV (2 mg/kg × day, i.
p.) were given starting 1 week after inoculation of A375 cells. Tumor and
tissue samples were obtained 24 h after finishing the treatment period.
For details of sample processing see [11]. Data are means ± S.D. for n =
8-9 mice in each condition. Values are mmol/g of tissue, except in A375
cells for which GSH is expressed as nmol/10
6 cells. *p < 0.01 comparing
different treatment conditions versus physiological saline (PS)-treated
control mice;
+p < 0.01 comparing tumor-bearing mice versus non-
tumor-bearing mice. GSH content in brain, lung, heart, glandular
stomach, skeletal muscle, bone marrow, ovary, and erythrocytes was not
affected by the growing tumor or by any of the treatments used (not
shown). Table S3: Hematology and clinical chemistry data in A375
melanoma-bearing mice treated to induce tumor suppression.
Standard cell count and chemistry were measured in peripheral blood
samples taken from the saphenous vein. Full treatment means the
combination of G3139 + verapamil + acivicin + paclitaxel protein-
binding particles + daunorubicin + X-rays (given as indicated in the
caption of Table 2). Tumor-bearing mice were sacrificed 1 or 30 days
after finishing the full treatment, whereas controls treated with
physiological saline were sacrificed 1 day after finishing the treatment.
Data are means ± S.D. for 8-9 different mice in each experimental
condition. *p < 0.05 comparing tumor-bearing mice versus non-tumor-
bearing mice;
+p < 0.05 comparing full treatment versus treatment with
physiological saline.
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